Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.58 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118241 | 0.98 | PARP10 (0.57) | PARP10PARP15PARP2MAPTTDP1 | |
| SCHEMBL3572304 | 0.94 | PARP15 (0.57) | PARP10PARP15PARP2MAPTTDP1 | |
| SCHEMBL9966867 | 0.90 | PARP15 (0.55) | PARP10PARP15PARP2TDP1 | |
| SCHEMBL23163613 | 0.81 | NFE2L2 (0.70) | MAPTTDP1L3MBTL1HPGDGRM2 | |
| SCHEMBL2460394 | 0.81 | TDP1 (0.68) | TDP1 | |
| SCHEMBL4886126 | 0.81 | PARP10 (0.55) | PARP10PARP15PARP2HPGDGRM2 | |
| SCHEMBL9280802 | 0.81 | TDP1 (0.50) | PARP10PARP15PARP2TDP1 | |
| SCHEMBL9280800 | 0.81 | TDP1 (0.50) | PARP10PARP15PARP2TDP1 | |
| SCHEMBL20870755 | 0.81 | TSHR (0.45) | PARP10PARP15PARP2TDP1MAOB | |
| SCHEMBL21579020 | 0.81 | PARP10 (0.58) | PARP10PARP15PARP2TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118838-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | PARP10 2051/4885PARP15 2903/4885PARP2 3290/4885 |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | PARP10 837/4885PARP15 1524/4885PARP2 1996/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | PARP10 2748/4885PARP15 4055/4885PARP2 4603/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | PARP10 927/4885PARP15 2433/4885PARP2 3330/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | PARP10 1357/4885PARP15 2362/4885PARP2 3702/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | PARP10 1159/4885PARP15 3040/4885PARP2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.